Profile data is unavailable for this security.
About the company
Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its Gynaecology products include Divatrone, Endoreg, Cystelia-M, Fibristone, Yuliprist, Deereg, and Lycored Softgel. Its Orthopaedics products include JP Tone Up, Metadec 50 Injection, Metadec 25 Injection, Indocap SR, and Indocap, Colla-2. Its other products include Equirex, Doxypal DR-L, JP Tone Syrup, and Lycored Syrup.
- Revenue in INR (TTM)2.27bn
- Net income in INR243.00m
- Incorporated1978
- Employees1.03k
- LocationJagsonpal Pharmaceuticals LtdT 210J, ShahpurjatGURGAON 122015IndiaIND
- Phone+91 1 244406710
- Fax+91 1 126494708
- Websitehttps://www.jagsonpal.com/
More ▼
Mergers & acquisitions
| Acquired company | JAGSNPHARM:NSI since announced | Transaction value |
|---|---|---|
| Yash Pharma Laboratories Pvt Ltd-Indian Business | 67.01% | -- |
| Yash Pharma Laboratories Pvt Ltd-Bhutan Business | 67.01% | 11.09m |
Data delayed at least 15 minutes, as of Nov 01 2024 13:52 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bajaj Healthcare Ltd | 4.76bn | -133.27m | 11.38bn | 944.00 | -- | -- | 77.32 | 2.39 | -4.82 | -10.30 | 172.62 | -- | -- | -- | -- | 5,041,608.00 | -- | 7.67 | -- | 14.11 | 48.43 | 33.26 | -2.80 | 7.99 | -- | 1.74 | -- | 4.90 | -26.69 | 5.04 | -122.55 | -- | 15.08 | -- |
| Ngl Fine Chem Ltd | 3.58bn | 420.29m | 12.21bn | 390.00 | 29.06 | -- | 31.67 | 3.41 | 68.03 | 68.03 | 580.00 | -- | -- | -- | -- | 9,188,328.00 | -- | 15.06 | -- | 19.58 | 52.02 | 43.53 | 11.73 | 13.15 | -- | 26.59 | -- | 3.06 | 21.79 | 17.20 | 101.58 | 15.47 | 14.49 | 0.00 |
| Bliss GVS Pharma Ltd | 8.00bn | 634.20m | 13.01bn | 831.00 | 20.79 | 1.29 | 13.06 | 1.63 | 5.94 | 5.94 | 75.55 | 96.05 | 0.6454 | 3.10 | 1.98 | 9,628,987.00 | 5.80 | 6.46 | 7.04 | 8.22 | 50.26 | 43.91 | 8.99 | 9.92 | 3.74 | -- | 0.0825 | 7.92 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| JG Chemicals Ltd | -100.00bn | -100.00bn | 13.44bn | 56.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -14.90 | -- | -43.84 | -- | -- | -- |
| Lincoln Pharmaceuticals Ltd | 5.92bn | 979.63m | 13.62bn | 1.70k | 13.90 | -- | 12.46 | 2.30 | 48.91 | 48.91 | 295.69 | -- | -- | -- | -- | 3,483,600.00 | -- | 13.95 | -- | 16.54 | 51.92 | 50.65 | 16.54 | 14.71 | -- | 60.93 | -- | 3.44 | 13.76 | 9.66 | 27.99 | 13.88 | 21.54 | 3.71 |
| Kopran Ltd | 6.37bn | 592.79m | 13.84bn | 358.00 | 19.77 | -- | 19.01 | 2.17 | 14.53 | 14.53 | 150.01 | -- | -- | -- | -- | 17,794,040.00 | -- | 8.47 | -- | 12.23 | 36.03 | 32.93 | 9.31 | 8.89 | -- | 27.17 | -- | 25.41 | 11.54 | 11.42 | 87.11 | 16.23 | 12.53 | -- |
| Jagsonpal Pharmaceuticals Ltd | 2.27bn | 243.00m | 14.37bn | 1.03k | 60.46 | 7.29 | 50.38 | 6.34 | 8.98 | 8.98 | 83.78 | 74.42 | 0.9703 | 5.13 | 9.92 | 2,213,181.00 | 10.39 | 10.95 | 12.40 | 13.29 | 58.16 | 58.13 | 10.71 | 9.21 | 2.60 | 32.84 | 0.0474 | 43.81 | -11.83 | 4.58 | -15.94 | 25.50 | -35.69 | 82.06 |
| Remus Pharmaceuticals Ltd | 2.12bn | 215.37m | 15.42bn | 48.00 | 70.08 | 17.75 | 57.37 | 7.26 | 37.34 | 37.34 | 374.91 | 147.42 | 1.46 | 7.61 | 3.56 | 44,270,750.00 | 17.80 | -- | 44.48 | -- | 22.67 | -- | 12.22 | -- | 1.12 | 55.56 | 0.0997 | -- | 371.94 | -- | 153.29 | -- | -- | -- |
| Zota Health Care Ltd | 1.98bn | -242.34m | 16.03bn | 445.00 | -- | -- | 3,431.57 | 8.09 | -9.27 | -9.27 | 76.32 | -- | -- | -- | -- | 4,452,605.00 | -- | -1.38 | -- | -1.85 | 49.86 | 35.95 | -12.23 | -1.33 | -- | -2.87 | -- | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
| Sigachi Industries Ltd | 4.10bn | 594.65m | 16.44bn | 991.00 | 30.75 | -- | 23.11 | 4.01 | 1.60 | 1.60 | 10.97 | -- | -- | -- | -- | 4,136,886.00 | -- | 14.77 | -- | 19.57 | 52.33 | 50.30 | 14.43 | 14.92 | -- | 7.19 | -- | 1.61 | 32.08 | 25.34 | 31.34 | 24.64 | 70.35 | -- |
| Beta Drugs Ltd | 2.96bn | 364.37m | 18.43bn | 371.00 | 50.57 | 11.73 | 39.86 | 6.23 | 37.90 | 37.90 | 307.59 | 163.43 | 1.31 | 4.51 | 4.17 | 7,970,723.00 | 16.10 | 15.10 | 23.91 | 22.23 | 38.73 | 39.77 | 12.32 | 12.38 | 1.51 | 17.81 | 0.0654 | 0.00 | 30.21 | 35.01 | 18.62 | 35.29 | -10.89 | -- |
| Syncom Formulations (India) Ltd | 2.91bn | 285.50m | 18.99bn | 802.00 | 61.97 | -- | 56.73 | 6.53 | 0.326 | 0.326 | 2.99 | -- | -- | -- | -- | 3,626,019.00 | -- | 7.50 | -- | 10.23 | 39.53 | 34.10 | 9.82 | 9.38 | -- | 7.67 | -- | -- | 17.45 | 7.12 | 26.13 | 17.95 | -- | -- |
Data as of Nov 01 2024. Currency figures normalised to Jagsonpal Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
0.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| WhiteOak Capital Asset Management Ltd.as of 30 Sep 2024 | 29.29k | 0.11% |
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
